Patterns of Progression on Posttreatment Imaging During [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy
Journal of Nuclear Medicine · 29.10.2026 · jnumed.126.272228
DOI: 10.2967/jnumed.126.272228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.10.2026. Verfasst von Surekha Yadav und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
We characterized patterns of treatment response and progression during [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT) using serial posttreatment SPECT/CT and prostate-specific membrane antigen (PSMA) PET imaging and evaluated cycle-by-cycle prostate-specific antigen (PSA)-imaging concordance.
Methods
We retrospectively analyzed 361 patients from 2 academic centers who received at least 2 cycles of [177Lu]Lu-PSMA RPT between May 2017 and March 2025. Posttreatment SPECT/CT scans were qualitatively evaluated to determine the site and pattern of response and progression, including PSMA low-avidity and PSMA-negative disease. Progression was defined by the appearance of new lesions or at least a 2-fold growth in preexisting lesions on SPECT/CT. PSA response was defined per Prostate Cancer Clinical Trials Working Group 3 criteria as at least a 50% decline from baseline. For cycle-by-cycle concordance analysis, PSA change was classified directionally as rising or falling relative to the prior cycle. In patients who paused or completed RPT after response, progression imaging was compared with the final on-treatment SPECT/CT scan.
Results
Overall, 290 of 361 (80%) patients demonstrated a decrease in lesion size or number on posttreatment imaging. Of 312 patients with baseline bone disease, 81% demonstrated a response on posttreatment imaging. In total, 156 of 361 patients (43%) demonstrated progression during treatment. New osseous lesions developed in 132 patients, of whom 89 (67%) had PSMA low-avidity disease. At cycle 2, 64% of new lesions were osseous, increasing to at least 90% by cycles 4-6. PSMA-negative progression occurred in 22 patients (6%), predominantly in the liver (n = 11) and lymph nodes (n = 8), with 59% detected at cycle 2. Among 81 patients with imaging available at PSA progression after treatment completion or pause, 74 (91%) had imaging progression; of these, 69 (93%) demonstrated osseous and 13 (18%) nodal progression. PSA and imaging were discordant in 25%-43% of patients across cycles, with discordance increasing from cycle 2 to cycle 6.
Conclusion
Progression during [177Lu]Lu-PSMA RPT occurs most frequently in bone, with 67% of patients with new osseous lesions demonstrating a PSMA low-avidity disease component. PSMA-negative progression is uncommon and tends to emerge early. PSA-imaging discordance is frequent, underscoring the need for integrated imaging assessment throughout treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
- Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.
- Department of Medicine, Division of Medical Oncology, University of California, San Francisco, California.
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
- Garvan Institute of Medical Research, Sydney, New South Wales, Australia; and.
- St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Zitieren
APA
Yadav, S., Khan, S., Moradi Tuchayi, A., Moradpour, M., Nwihim, S., de Kouchkovsky, I., Flavell, R. R., Aggarwal, R. R., Emmett, L., & Hope, T. A. (2026). Patterns of Progression on Posttreatment Imaging During [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy. Journal of Nuclear Medicine, jnumed.126.272228. https://doi.org/10.2967/jnumed.126.272228
Vancouver
Yadav S, Khan S, Moradi Tuchayi A, Moradpour M, Nwihim S, de Kouchkovsky I, et al. Patterns of Progression on Posttreatment Imaging During [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2026:jnumed.126.272228. doi:10.2967/jnumed.126.272228
BibTeX
@article{Yadav2026,
author = {Yadav, Surekha and Khan, Sobia and Moradi Tuchayi, Abuzar and Moradpour, Moein and Nwihim, Stellamaris and de Kouchkovsky, Ivan and Flavell, Robert R and Aggarwal, Rahul R and Emmett, Louise and Hope, Thomas A},
title = {Patterns of Progression on Posttreatment Imaging During [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy},
journal = {Journal of Nuclear Medicine},
year = {2026},
pages = {jnumed.126.272228},
doi = {10.2967/jnumed.126.272228}
}
EUVIMED